R

Raúl Fernández Prado

Hospital Universitario Fundación Jiménez Díaz

Publishes on Chronic Kidney Disease and Diabetes, Renal Diseases and Glomerulopathies, Dialysis and Renal Disease Management. 8 papers and 637 citations.

8Publications
637Total Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

RICORS2040: the need for collaborative research in chronic kidney disease
Alberto Ortíz, Marta Roger, Víctor Jiménez et al.|Clinical Kidney Journal|2021
Cited by 122Open Access

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true.

Building CRESCENDO – a global registry of glomerulonephritis with crescents
Vanja Ivković, Andreas Kronbichler, Annette Bruchfeld et al.|Clinical Kidney Journal|2026
Cited by 0Open Access

Abstract Crescents represent a non-specific mechanism in response to severe glomerular injury and show a temporal pattern evolving from cellular and fibrocellular to fibrous. Crescentic glomerulonephritis (GN) is defined as ≥50% cellular crescentic glomeruli on kidney histology and is frequently characterized by rapid deterioration of kidney function and features of nephritis. However, little is known on how different types and proportions of crescents affect prognosis and this may differ across diseases forming the spectrum of crescentic GN. To explore this we have devised CRESCENDO, a multinational, longitudinal, observational registry collecting clinical, laboratory and histopathology data from patients with GN and crescents. The registry aims to enroll patients from all continents to explore the prognostic value of crescents on a continuum, ranging from one crescentic glomerulus to 100% crescents on biopsy. We also aim to explore other potential prognostic and diagnostic predictors of a wide range of outcomes (not limited to mortality and kidney survival, but also infections, malignancy, and kidney function recovery), leverage exploratory machine learning approaches of scanned kidney biopsies and test the efficacy and safety of different therapies across crescentic GN spectrum. The findings of CRESCENDO will hopefully help close gaps in the understanding of crescentic GN and will generate further hypotheses providing the basis for subsequent research.

FP599VITAMIN D THERAPY AND MORTALITY IN HEMODIALYSIS PATIENTS
Ricardo Villa‐Bellosta, Soledad Pizarro Sánchez, Raquel Esteras Rubio et al.|Nephrology Dialysis Transplantation|2018
Cited by 0Open Access

throughout study followup. No difference in ESA consumption was noted [median(IQR): 10(6-15) vs 6(4-9) 10^3 UI/week for standard vs intense PTH control study arm]. A post-hoc analysis also excluded an overall association of PTH lowering and ESA use. Although this is a RCT with a pre-specified sample size, the open-label design and the poor protocol adherence of the attending physicians should be considered when study results are analyzed CONCLUSIONS: The OPTIMAL ESRD TREATMENT study fail to demonstrate an association between PTH and anemia control. Future endeavors are needed to elucidate whether current results are due to the poor protocol adherence noted in the study Table 1 Variable Intensive Standard Age (years) 68(11) 64(21) Dialysis vintage (month) 42[17-83] 47[21-73] Women (%) 28 36 Systolic Blood Pressure (mmHg) 146(30) 145(24) Diastolic Blood Pressure (mmHg) 72(12) 70(12) Hypertension(%) 84 76 Diabetes(%) 32 44 Coronary artery disease (%) 28 16 Cerbrovascular disease (%) 20 16 PTH (pg/ml)